Telitacicept
- Generic Name
- Telitacicept
- Drug Type
- Biotech
- CAS Number
- 2136630-26-5
- Unique Ingredient Identifier
- 1FHM3D7Z49
- Indication
用于治疗系统性红斑狼疮（SLE）、类风湿性关节炎等多种自身免疫疾病。
小知识：SLE症状表现多样，如面部出现红斑、关节肿痛、对光过敏、口腔溃疡等，随着病情的进展可导致肾脏、心血管等全身多系统、多器官的不可逆损害，严重威胁生命。目前，我国SLE患病人数超过100万，居全球之首，且多发于15-45岁的年轻女性，女性患病率为男性的10.1倍。
Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis
- Conditions
- Myasthenia GravisAutoimmune Diseases
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Target Recruit Count
- 30
- Registration Number
- NCT06723548
Immune Cell Subsets in SLE Patients Treated with Telitacicept
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 50
- Registration Number
- NCT06677801
- Locations
- 🇨🇳
the second affiliated hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN)
- Conditions
- Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN)
- Interventions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Renmin Hospital of Wuhan University
- Target Recruit Count
- 15
- Registration Number
- NCT06656962
- Locations
- 🇨🇳
Renmin hospital of Wuhan University, Wuhan, Hubei, China
Efficacy and Safety of Telitacicept in IgAN
- Conditions
- IgA Nephropathy (IgAN)Kidney DiseasesTelitaciceptGlucocorticoid
- Interventions
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 118
- Registration Number
- NCT06654596
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, China
The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy
- Conditions
- Primary Membranous Nephropathy
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-09-26
- Lead Sponsor
- Renmin Hospital of Wuhan University
- Target Recruit Count
- 172
- Registration Number
- NCT06614985
- Locations
- 🇨🇳
Renmin Hospital of Wuhan university, Wuhan, Hubei China, China
A Single Dose Study to Investigate the Pharmacokinetics (PK) of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in Chinese Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 248
- Registration Number
- NCT06549959
- Locations
- 🇨🇳
The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
🇨🇳West China Hospital of Sichuan University, Chengdu, Sichuan, China
🇨🇳Tianjin People's Hospital, Tianjin, Tianjin, China
The Safety and Efficacy of Telitacicept in the Treatment of Systemic Sclerosis
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06546540
- Locations
- 🇨🇳
Peking Third Hospital, Beijing, China
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT06456567
- Locations
- 🇺🇸
Hemet site, Hemet, California, United States
🇺🇸Menifee site, Menifee, California, United States
🇺🇸Rockford site, Rockford, Illinois, United States
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (RemeMG)
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06456580
- Locations
- 🇺🇸
Orange Site, Orange, California, United States
🇺🇸Lexington Site, Lexington, Kentucky, United States
🇺🇸Foxboro Site, Foxboro, Massachusetts, United States
Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 38
- Registration Number
- NCT06375005
- Locations
- 🇨🇳
Hangzhou First People's Hospital, Hangzhou, Zhejiang, China
🇨🇳Sir Run Run Shaw Hospital, Zhejiang University School Of Medicine, Hangzhou, Zhejiang, China
🇨🇳Changxing People's Hospital, Huzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.